Exane Asset Management Biomarin Pharmaceutical Inc Transaction History

Exane Asset Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 05, 2019	SELL	$80.14 - $106.07 $6.64 Million - $8.79 Million	-82,881 Closed	0 $0
Q3 2018 Nov 16, 2018	SELL	$93.92 - $105.72 $3.03 Million - $3.42 Million	-32,305 Reduced 28.05%	82,881 $0
Q2 2018 Sep 06, 2018	SELL	$76.01 - $99.03 $1.36 Million - $1.77 Million	-17,881 Reduced 13.44%	115,186 $0
Q1 2018 Apr 30, 2018	SELL	$77.67 - $92.63 $2.18 Million - $2.6 Million	-28,122 Reduced 17.45%	133,067 $0
Q4 2017 Feb 08, 2018	BUY	$80.76 - $95.13 $3.31 Million - $3.9 Million	40,989 Added 34.1%	161,189 $0
Q3 2017 Oct 13, 2017	BUY	$80.6 - $94.95 $9.69 Million - $11.4 Million	120,200	120,200 $11.2 Billion

628

183M

1.67M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.